Patrick Innamarato1,2, Jennifer Morse1, Amy Mackay1, Sarah Asby1, Matthew Beatty1, Jamie Blauvelt1, Scott Kidd1, John E Mullinax1,3, Amod A Sarnaik1,4, Shari Pilon-Thomas5. 1. Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, 12902 USF Magnolia Dr, Tampa, FL, 33612, USA. 2. Cancer Biology Ph.D. Program, University of South Florida, Tampa, FL, USA. 3. Sarcoma Department, H. Lee Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL, 33606, USA. 4. Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. 5. Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, 12902 USF Magnolia Dr, Tampa, FL, 33612, USA. shari.pilon-thomas@moffitt.org.
Abstract
BACKGROUND: Chemotherapy regimens that include the utilization of gemcitabine are the standard of care in pancreatic cancer patients. However, most patients with advanced pancreatic cancer die within the first 2 years after diagnosis, even when treated with standard of care chemotherapy. This study aims to explore combination therapies that could boost the efficacy of standard of care regimens in pancreatic cancer patients. METHODS: In this study, we used PV-10, a 10% solution of rose bengal, to induce the death of human pancreatic tumor cells in vitro. Murine in vivo studies were carried out to examine the effectiveness of the direct injection of PV-10 into syngeneic pancreatic tumors in causing lesion-specific ablation. Intralesional PV-10 treatment was combined with systemic gemcitabine treatment in tumor-bearing mice to investigate the control of growth among treated tumors and distal uninjected tumors. The involvement of the immune-mediated clearance of tumors was examined in immunogenic tumor models that express ovalbumin (OVA). RESULTS: In this study, we demonstrate that the injection of PV-10 into mouse pancreatic tumors caused lesion-specific ablation. We show that the combination of intralesional PV-10 with the systemic administration of gemcitabine caused lesion-specific ablation and delayed the growth of distal uninjected tumors. We observed that this treatment strategy was markedly more successful in immunogenic tumors that express the neoantigen OVA, suggesting that the combination therapy enhanced the immune clearance of tumors. Moreover, the regression of tumors in mice that received PV-10 in combination with gemcitabine was associated with the depletion of splenic CD11b+Gr-1+ cells and increases in damage associated molecular patterns HMGB1, S100A8, and IL-1α. CONCLUSIONS: These results demonstrate that intralesional therapy with PV-10 in combination with gemcitabine can enhance anti-tumor activity against pancreatic tumors and raises the potential for this strategy to be used for the treatment of patients with pancreatic cancer.
BACKGROUND: Chemotherapy regimens that include the utilization of gemcitabine are the standard of care in pancreatic cancerpatients. However, most patients with advanced pancreatic cancer die within the first 2 years after diagnosis, even when treated with standard of care chemotherapy. This study aims to explore combination therapies that could boost the efficacy of standard of care regimens in pancreatic cancerpatients. METHODS: In this study, we used PV-10, a 10% solution of rose bengal, to induce the death of humanpancreatic tumor cells in vitro. Murine in vivo studies were carried out to examine the effectiveness of the direct injection of PV-10 into syngeneic pancreatic tumors in causing lesion-specific ablation. Intralesional PV-10 treatment was combined with systemic gemcitabine treatment in tumor-bearing mice to investigate the control of growth among treated tumors and distal uninjected tumors. The involvement of the immune-mediated clearance of tumors was examined in immunogenic tumor models that express ovalbumin (OVA). RESULTS: In this study, we demonstrate that the injection of PV-10 into mousepancreatic tumors caused lesion-specific ablation. We show that the combination of intralesional PV-10 with the systemic administration of gemcitabine caused lesion-specific ablation and delayed the growth of distal uninjected tumors. We observed that this treatment strategy was markedly more successful in immunogenic tumors that express the neoantigen OVA, suggesting that the combination therapy enhanced the immune clearance of tumors. Moreover, the regression of tumors in mice that received PV-10 in combination with gemcitabine was associated with the depletion of splenic CD11b+Gr-1+ cells and increases in damage associated molecular patterns HMGB1, S100A8, and IL-1α. CONCLUSIONS: These results demonstrate that intralesional therapy with PV-10 in combination with gemcitabine can enhance anti-tumor activity against pancreatic tumors and raises the potential for this strategy to be used for the treatment of patients with pancreatic cancer.
Authors: Robert Gastpar; Mathias Gehrmann; Maria A Bausero; Alexzander Asea; Catharina Gross; Josef A Schroeder; Gabriele Multhoff Journal: Cancer Res Date: 2005-06-15 Impact factor: 12.701
Authors: Katherine H Parker; Pratima Sinha; Lucas A Horn; Virginia K Clements; Huan Yang; Jianhua Li; Kevin J Tracey; Suzanne Ostrand-Rosenberg Journal: Cancer Res Date: 2014-08-27 Impact factor: 12.701
Authors: Tavis A Read; Aaron Smith; Janine Thomas; Michael David; Matthew Foote; Michael Wagels; Andrew Barbour; B Mark Smithers Journal: J Surg Oncol Date: 2018-03-12 Impact factor: 3.454
Authors: Filippo Veglia; Vladimir A Tyurin; Dariush Mohammadyani; Maria Blasi; Elizabeth K Duperret; Laxminarasimha Donthireddy; Ayumi Hashimoto; Alexandr Kapralov; Andrew Amoscato; Roberto Angelini; Sima Patel; Kevin Alicea-Torres; David Weiner; Maureen E Murphy; Judith Klein-Seetharaman; Esteban Celis; Valerian E Kagan; Dmitry I Gabrilovich Journal: Nat Commun Date: 2017-12-14 Impact factor: 14.919
Authors: Michio Kurosu; Katsuhiko Mitachi; Junshu Yang; Edward V Pershing; Bruce D Horowitz; Eric A Wachter; John W Lacey; Yinduo Ji; Dominic J Rodrigues Journal: Molecules Date: 2022-01-05 Impact factor: 4.411